Switched from finasteride to dut
    8/11/2026

    From the encyclopedia
    Finasteride →

    Frontline, gold standard treatment for combatting androgenic alopecia

    Dutasteride →

    Heavy duty finasteride that comes with higher risks

    At a glance
    In this treatment experience post, the primary subjects mentioned are
    💊 Finasteride (oral) 1 mg 1x daily 6 years
    💊 Dutasteride (oral) 0.5 mg 1x daily 5 months
    the tone is 😐 neutral.

    Other terms

    The user switched from finasteride to dutasteride 0.5 mg daily due to worsening hair loss and is seeking opinions on any noticeable regrowth or improvement. Some users suggest there might be more thick hairs, while others find it hard to compare due to different photo angles.
    View this post in the Community →

    Similar Community Posts Join

    6 / 6 results

    Related Research

    6 / 6 results
      Female Pattern Alopecia: Current Perspectives

      research Female pattern alopecia: current perspectives

      42 citations , August 2013 in “International Journal of Women's Health”
      This review discusses the current therapeutic options for female pattern hair loss and emphasizes the need for managing patient expectations of permanent regrowth, reporting no new clinical results.
      Role and Mechanisms of Phytochemicals in Hair Growth and Health

      research Role and Mechanisms of Phytochemicals in Hair Growth and Health

      2 citations , January 2023 in “Pharmaceuticals”
      This review discusses factors affecting hair health, types of alopecia, and the potential of phytochemicals in managing hair loss but reports no new clinical results; it highlights the need for further studies.
      Primary Cicatricial Alopecia: Treatment Approaches and Classification

      research Primary cicatricial alopecia

      95 citations , November 2016 in “Journal of The American Academy of Dermatology”
      This article reviews primary cicatricial alopecias, focusing on lymphocytic forms such as chronic cutaneous lupus erythematosus, according to a classification by the North American Hair Research Society, and reports no new clinical results.